• 中文名稱：

• 奧拉帕尼

• 英文名稱：

• olaparib

• 英文別名：

• AZD-2281;

  azd2281 Olaparib;

• CAS號(hào)：

• 763113-22-0

• 分子式：

• C24H23FN4O3

• 分子量：

• 434.46300

• 精確質(zhì)量：

• 434.17500

• PSA：

• 86.37000

Olaparib (AZD-2281, trade name Lynparza) is an FDA-approved targeted therapy for cancer, developed by KuDOS Pharmaceuticals and later by AstraZeneca. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers. In December 2014, olaparib was approved for use as a single agent by the EMA and the FDA. The FDA approval is in for germline BRCA mutated (gBRCAm) advanced ovarian cancer that has received three or more prior lines of chemotherapy.